To begin to compare the effect of unencapsulated IL‐1α and IL‐1α‐MPs, male C57Bl/6 mice (n = 5–10 mice/treatment group) bearing mEERL HNSCC tumors were treated with saline, murine rIL‐1α, IL‐1α‐MPs (3.75 μg rIL‐1α/mouse, i.p) and corresponding Blank MPs on Treatment Days 1 and 5 (total = 7.5 μg IL‐1α, Figure 3a). The gene discussed is IL1A; the disease is head and neck squamous cell carcinoma.